Morgan Stanley analyst Terence Flynn raised the firm’s price target on Royalty Pharma (RPRX) to $54 from $51 and keeps an Overweight rating on the shares. Year-to-date, large cap pharma and biotech companies have both underperformed given the macro environment, while multiple areas of policy uncertainty remain, including drug pricing dynamics, tariff and transfer pricing exposure, and FDA staffing changes, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RPRX:
- Strategic Financial Agreements and Promising Drug Developments Justify Buy Rating for Royalty Pharma
- Royalty Pharma’s Strategic Partnership with Revolution Medicines: A High-Reward Investment Opportunity
- Royalty Pharma announces $2B funding arrangement with Revolution Medicines
- Revolution Medicines enters $2B funding agreement with Royalty Pharma
- Royalty Pharma 12M share Spot Secondary priced at $33.25